A randomized, double-blind, placebo-controlled study of tamibarotene/azacitidine versus placebo/azacitidine in newly diagnosed adult patients selected for RARA+ HR-MDS (SELECT-MDS-1).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Amy Elizabeth Dezern, Giovanni Marconi, Dries Deeren, Maria Diez Campelo, Michael Lübbert, Pramila Krishnamurthy, Zsolt Nagy, Grzegorz Basak, Elena Morozova, Klaus Geissler, Yishai Ofran, Heather Kelley, Angela Volkert, Kristen Baker, Qing Kang-Fortner, Catherine Madigan, David A. Roth, Michael Kelly, Pierre Fenaux
Institutions: Johns Hopkins University, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, AZ Delta, Complejo Hospitalario de Salamanca, University Medical Center Freiburg, King's College Hospital, Semmelweis University, Medical University of Warsaw, Klinik Hietzing, Hebrew University of Jerusalem, Shaare Zedek Medical Center, Bikur Cholim Hospital, Syros Pharmaceuticals (United States), Hôpital Saint-Louis
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281916232